Christopher Drinjak

Christopher specialises in assisting lawyers to enhance their skills, win new instructions, manage client relationships and augment their international networks.

He has worked in senior business development roles based in the UK and in Germany, and currently is the business development lead for the firm's Life Sciences & Healthcare industry sector.

CV

Since 2019 Senior business development manager (Life sciences and healthcare), and Senior business development manager (Disputes and investigations, IP, Commercial tech and data, and Patents), Taylor Wessing

2011 - 2018 Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins

2001 - 2011 Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance

职业发展

2011 - 2018 Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins

2001 - 2011 Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance

教育

2001 Masters of business administration, International University, Germany

1996 M.A. in musicology, Michigan State University, US

1994 B.A. in German and B.A. in Music Performance, Michigan State University, US

Christopher Drinjak

专长

行业

CV

职业发展

教育

语言

Christopher Drinjak

专长

行业

CV

职业发展

教育

语言

Related news & insights

Update from Berlin: Federal government tightens cannabis policy

Partner appointment Margot van Gerwen

Data Provision under the Data Act in the Life Sciences Environment

EUDAMED-Rollout: From a Perpetual Construction Site to Regulatory Reality

Everything Is Relative? Implications of the CJEU Judgment C-413/23 (SRB/EDPS) for the Secondary Use of Personal Data in Research Practice

The European Innovation Act: From Regulatory Fragmentation to Coherent Innovation Governance

Pre-trial discovery before the UPC? – Pharmaceuticals, Trade fairs and beyond

Advising EpilepsyGTx on its US$33 million Series A financing

Biotechnology as a security issue: Why dual-use control and adaptive regulation are crucial for national sustainability

Advertising skinny jabs – regulators react

相关人员

与我会面：